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Background: Reduced left ventricular ejection fraction (LVEF) is an important predictor of increased mortality in patients with stable coronary 
artery disease and acute coronary syndromes. The impact of reduced LVEF across the full spectrum of patients undergoing PCI and the relative 
outcomes of the treatment with bivalirudin (BIV) versus heparin plus a GPIIb/IIIa inhibitor (H+GPI) according to LVEF is not known.
Methods: We pooled patient level data from the REPLACE-2, ACUITY and HORIZONS-AMI trials including 18,819 pts undergoing PCI for stable 
ischemic syndromes, unstable angina, non ST-segment elevation MI (STEMI), and STEMI. We examined 1 year mortality according to no, moderate 
and severe impairment of left ventricular systolic function (LVEF > 50%, 35-50% and <35% respectively) as assessed at baseline.
Results: The figure shows (A) the unadjusted hazard ratios for mortality and (B) the treatment effect of BIV v. H+GPI on mortality in all patients 
undergoing PCI after adjustment for LVEF. Higher mortality is evident with decrements of LVEF, whereas BIV appears to provide a greater survival 
advantage in patients with low LVEF (interaction p value = 0.06).
Conclusions: In this patient-level pooled analysis of patients undergoing PCI for the full spectrum of indications from stable ischemia to STEMI, 
moderate and severe reduction of LVEF was associated with markedly increased 1-year mortality, and BIV conferred a survival advantage in the 
highest risk patients.
 
